BridgeBio gains as Q1 sales of heart condition drug beat estimates

Shares of drugmaker BridgeBio Pharma BBIO.O rise 7.08% to $39 after market

Co posts Q1 Attruby sales of $36.7 million, beating estimates of $13.10 million, according to data compiled by LSEG

Attruby is used to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail

As of April 25, 2,072 unique patient prescriptions for Attruby have been written by 756 healthcare providers since FDA approval in November 2024

Attruby launch continues to be strong so far and has raised market expectations — BMO Capital Markets

Stock up ~32% YTD